SOLID: Management of Dyslipidemia in Adult Type 2 Diabetes Patients in India
Sponsor
AstraZeneca (Industry)
Overall Status
Completed
CT.gov ID
NCT01292018
Collaborator
(none)
5,400
12
Study Details
Study Description
Brief Summary
The purpose of study to assess the control of dyslipidemia in the Indian diabetic population treated with any hypolipidemic agent.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Study Design
Study Type:
Observational
Actual Enrollment
:
5400 participants
Observational Model:
Cohort
Time Perspective:
Cross-Sectional
Official Title:
A Non Interventional, Cross Sectional, Epidemiological Study on the Management of Dyslipidemia in Type 2 DM Adult Patients in India
Study Start Date
:
Feb 1, 2011
Actual Study Completion Date
:
Feb 1, 2012
Outcome Measures
Primary Outcome Measures
- Proportion of type 2 diabetic dyslipidemia patients achieving the target LDL goal according to ADA 2010. These patients should be on stable dose of Lipid Lowering Drugs(LDL) for at least 3 months []
Secondary Outcome Measures
- Proportion of dyslipidemia control rate according to american diabetes Association (ADA) 2010 criteria by age and gender []
- Control of dyslipidemia by Lipid Lowering Drugs (LLDs) drugs alone or combination []
- Control of dyslipidemia by all commercial available brands hypolipidemics drugs []
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
-
Adult who is a known Type 2 diabetic as per the ADA 2010 criteria OR controlled diabetic (taking any antidiabetic medication)
-
Patients in the study will have been on lipid lowering drugs at a stable dose for the last three months before the designated study visit.
Exclusion Criteria:
-
Type 1 diabetic patients
-
Patients with a history of hepatic or renal diseases
-
Hypertension due to organic diseases
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- AstraZeneca
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01292018
Other Study ID Numbers:
- NIS-CIN-DUM-2010/1
First Posted:
Feb 9, 2011
Last Update Posted:
Feb 21, 2013
Last Verified:
Feb 1, 2013
Keywords provided by AstraZeneca
Additional relevant MeSH terms: